Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

While Bayer’s consumer and crop science divisions continued to slide—both in the fourth quarter and in 2024 overall—the ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Bayer HealthCare's Eylea (aflibercept solution for injection into the eye) has been approved by the European Commission for the treatment of visual impairment due to diabetic macular oedema (DMO).

EYLEA HD (known as Eylea™ 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the ...

Bayer has submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the ...

Bayer CEO warns of tough 2025 as turnaround plan beds in Sofinnova raises €1.2bn to back 'up to 60' companies Roche ends the 30-year US hiatus in new stroke drugs ...

Eylea HD is developed by Regeneron in partnership with Bayer. The QUASAR trial is being conducted by Bayer as part of its collaboration agreement with Regeneron. Regeneron holds exclusive rights ...

Bayer earns license revenues from JNJ for Xarelto sales in the United States. Sales of the ophthalmology drug, Eylea, increased 0.9% to €833 million, driven by higher volumes and prices.